MedTrace Logo

Blue Note Therapeutics Product BNT 103 Usability and User Engagement

NCT05032404 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-10-19

No results posted yet for this study

Summary

This test aims to explore product development-focused usability and user engagement.

Conditions

  • Breast Cancer Female

Interventions

DEVICE

BNT103

BNT-103™ is a prescription digital therapeutic specifically designed to treat the symptoms of anxiety and depression related to cancer. There are 10 sessions provided over approximately 10 weeks.

Sponsors & Collaborators

  • Healthcare Innovation Technology Lab

    collaborator INDUSTRY

  • Blue Note Therapeutics

    lead INDUSTRY

Principal Investigators

  • Dianne Shumay, PhD · Blue Note Therapeutics, Inc

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2021-10-26
Completion
2021-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05032404 on ClinicalTrials.gov